Pacira Pharmaceuticals Inc (PCRX) Analysts See $-0.22 EPS

October 13, 2017 - By Winifred Garcia

 Pacira Pharmaceuticals Inc (PCRX) Analysts See $ 0.22 EPS
Investors sentiment increased to 1.62 in Q2 2017. Its up 0.45, from 1.17 in 2017Q1. It increased, as 23 investors sold Pacira Pharmaceuticals Inc shares while 45 reduced holdings. 37 funds opened positions while 73 raised stakes. 39.35 million shares or 1.09% less from 39.78 million shares in 2017Q1 were reported.
Blackrock reported 3.48M shares. Healthcor L P reported 3.09% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Tower Ltd (Trc) invested in 0% or 100 shares. 10,370 were accumulated by Bluecrest Ltd. Metropolitan Life Insur Ny holds 0.01% or 26,681 shares. Wellington Mngmt Grp Inc Limited Liability Partnership invested in 16,403 shares. Elk Creek Limited Com holds 552,656 shares or 1.71% of its portfolio. Ameriprise Fin reported 0.01% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Clough Prtn L P stated it has 19,500 shares or 0.06% of all its holdings. Trexquant Invest Lp stated it has 0.06% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Nationwide Fund Advisors has invested 0.01% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Renaissance Lc accumulated 17,800 shares. Hanseatic Mngmt Svcs reported 15 shares. 17,575 are held by Tfs Limited Liability Corporation. California Pub Employees Retirement Sys accumulated 0% or 64,700 shares.

Since May 15, 2017, it had 0 buys, and 9 sales for $2.59 million activity. Scibetta James S had sold 1,966 shares worth $85,169. Williams Kristen Marie sold $1.07 million worth of stock or 21,041 shares. Another trade for 4,311 shares valued at $186,757 was sold by STACK DAVID M. Shares for $33,227 were sold by Jones James B. 768 shares were sold by Braunstein Scott, worth $33,271.

Analysts await Pacira Pharmaceuticals Inc (NASDAQ:PCRX) to report earnings on November, 1. After $-0.29 actual earnings per share reported by Pacira Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -24.14 % EPS growth. About 574,106 shares traded. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has risen 12.40% since October 13, 2016 and is uptrending. It has underperformed by 4.30% the S&P500.

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Ratings Coverage

Among 19 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 12 have Buy rating, 0 Sell and 7 Hold. Therefore 63% are positive. Pacira Pharmaceuticals had 59 analyst reports since July 28, 2015 according to SRatingsIntel. As per Monday, May 29, the company rating was maintained by Canaccord Genuity. Mizuho maintained the stock with “Buy” rating in Tuesday, July 25 report. Wedbush maintained the shares of PCRX in report on Wednesday, July 19 with “Buy” rating. Canaccord Genuity initiated the shares of PCRX in report on Wednesday, February 22 with “Buy” rating. On Monday, September 25 the stock rating was maintained by Needham with “Buy”. The firm earned “Buy” rating on Tuesday, January 3 by H.C. Wainwright. The rating was maintained by Jefferies with “Buy” on Friday, July 14. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) earned “Buy” rating by Piper Jaffray on Tuesday, July 25. As per Friday, July 14, the company rating was maintained by Cowen & Co. The stock has “Buy” rating by Brean Capital on Friday, February 26.

Pacira Pharmaceuticals, Inc. is a holding company. The company has market cap of $1.37 billion. The Firm is a pharmaceutical firm focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. It currently has negative earnings. The Company’s lead product candidate is EXPAREL , which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia.

More notable recent Pacira Pharmaceuticals Inc (NASDAQ:PCRX) news were published by: which released: “Pacira Pharmaceuticals (PCRX) Q2 2017 Results – Earnings Call Transcript” on August 02, 2017, also with their article: “Pacira Pharmaceuticals CEO to Testify at White House Opioid Crisis Commission …” published on September 27, 2017, published: “Pacira Pharmaceuticals (PCRX) Q1 2017 Results – Earnings Call Transcript” on May 04, 2017. More interesting news about Pacira Pharmaceuticals Inc (NASDAQ:PCRX) were released by: and their article: “Pacira Pharmaceuticals Appoints Mark I. Froimson, MD, to Board of Directors” published on June 15, 2017 as well as‘s news article titled: “Pacira’s EXPAREL Reducing Opioid Consumption” with publication date: September 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.